Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.

José Luis Martín-VarillasBelén Atienza-MateoVanesa Calvo-RioEmma BeltránJuan Sánchez-BursónAlfredo AdánMarisa Hernández-GarfellaElia Valls-PascualAgustí Sellas-FernándezNorberto OrtegoOlga MaízIgnacio TorreCruz Fernández-EsparteroVega JovaniDiana PeiteadoDavid Díaz ValleElena AurrecoecheaMiguel A CaracuelAlfredo J García-GonzálezEnrique Raya ÁlvarezNuria Vegas-RevengaRosalía Demetrio-PabloSantos CastañedaMiguel A González-GayJose Luis Hernández-Hernández Ricardo Blanco-Alonsonull null

Published in: The Journal of rheumatology (2020)

IFX seems to be effective and relatively safe in White patients with refractory BD uveitis. IFX optimization is effective, safe, and cost-effective.

Keyphrases

end stage renal disease
juvenile idiopathic arthritis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
quality improvement
patient reported outcomes
childhood cancer